Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues Abstract #1363

Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Aim(s): To assess the effect of Peptide Receptor Radionuclide Therapy (PRRT) on refractory carcinoid syndrome.
Materials and methods: A retrospective analysis included 35 patients with advanced NETs and refractory carcinoid syndrome despite maximum doses of SSAs, who had Lutetium177 DOTA Octreotate PRRT. Pre- and post- PRRT assessment of flushing, bowel frequency and 24h urine 5-Hydroxyindoleacetic Acid (5-HIAA) was performed.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1416 Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Advanced Bronchial Neuroendocrine Tumours
Introduction: There is not established treatment pathway in advanced bronchial neuroendocrine tumours(bNETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
Keywords: PRRT, bronchial NETs
#1814 Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT)
Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Georgios Demetriou
Keywords: PRRT, Y90, Lu-177
#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K, ...
#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome
Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT VIP
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis